Using AI to improve tests for cancer cells in fluid from malignant effusions
Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cells
This study is testing a new, less invasive way to find and analyze cancer cells in fluid buildup from metastatic breast cancer, using advanced technology to help doctors choose the best treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10946304 on NIH RePORTER |
What this research studies
This research focuses on developing innovative liquid biopsy tests that utilize artificial intelligence to isolate tumor cells from malignant effusions, which are fluid accumulations often seen in metastatic breast cancer. By analyzing these fluids instead of traditional tissue samples, the study aims to identify drug targets and predictors of treatment response, addressing significant clinical needs. The approach involves creating detailed morphological atlases of circulating tumor cells to enhance the accuracy of cancer profiling. This method could provide a less invasive alternative for patients, allowing for better-informed treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer who experience malignant effusions.
Not a fit: Patients with early-stage breast cancer or those without malignant effusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with metastatic breast cancer.
How similar studies have performed: Other research has shown promise in using liquid biopsies for cancer detection, but this specific AI-assisted approach is relatively novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Magbanua, Mark Jesus — University of California, San Francisco
- Study coordinator: Magbanua, Mark Jesus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.